Media Coverage

Dr. Chovatiya is passionate about leveraging both digital and print media for impactful and high quality education for medical and non-medical communities. He uniquely possesses a reliable, clear, and insightful point-of-view backed in clinical evidence and scientific data. He is widely sought after for his communication skills and is a frequent contributor to many major media outlets.

1. Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options. Dermatology News. https://www.mdedge.com/dermatology/article/267179/atopic-dermatitis/expert-frames-factors-consider-among-atopic-dermatitis. December 27, 2023.
2. FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Patients 9 Years and Older. Practical Dermatology. https://practicaldermatology.com/news/fda-approves-arcutis-zoryve-roflumilast-topical-foam-03-for-the-treatment-of-seborrheic-dermatitis-in-patients-9-years-and-older. December 16, 2023. 
3. Relief from Core AD Symptoms: Topical Cream Treatments for Moderate to Severe Atopic Dermatitis in Adults and Pediatrics. Dermatology Times. https://www.dermatologytimes.com/between-the-lines/relief-from-core-ad-symptoms-topical-cream-treatments-for-moderate-to-severe-atopic-dermatitis. December 15, 2023.
4. How does lebrikizumab perform across different racial and ethnic subgroups? Dermatology News. https://www.mdedge.com/dermatology/article/267049/atopic-dermatitis/how-does-lebrikizumab-perform-across-different-racial. December 15, 2023.
5. Looking Back on Dermatology's Historic 2023 with Raj Chovatiya, MD, PhD. HCPLive. https://www.hcplive.com/view/looking-back-dermatology-historic-2023-raj-chovatiya-md-phd. December 11, 2023.
6. Vitiligo Case Report: Rapid Onset of White Patches on Face, Neck, and Arms. Dermatology Times. https://www.dermatologytimes.com/view/vitiligo-case-report-rapid-onset-of-white-patches-on-face-neck-and-arms. December 11, 2023.
7. Poster Pearl: Itch Control Matters Most to Patients with Moderate-to-Severe Atopic Dermatitis. ReachMD. https://reachmd.com/programs/dermconsult/poster-pearl-itch-control-matters-most-to-patients-with-moderate-to-severe-atopic-dermatitis/15594. December 6, 2023.
8. Strategies for the Long-Term Control of Atopic Dermatitis. ReachMD. https://reachmd.com/programs/dermconsult/strategies-for-the-long-term-control-of-atopic-dermatitis/15593. December 6, 2023.
9. Practical Tips for Managing Actinic Keratosis with Photodynamic Therapy in the Clinic. HCPLive. https://www.hcplive.com/medcast-videos/practical-tips-for-managing-actinic-keratosis-with-photodynamic-therapy-in-the-clinic. November 28, 2023.
10. Dr Raj Chovatiya Summarizes Clinical Implications of Type 2 Inflammation. American Journal of Managed Care. https://www.ajmc.com/view/dr-raj-chovatiya-summarizes-clinical-implications-of-type-2-inflammation. November 24, 2023.
11. 2023 Innovations Garnering Gratitude. Dermatology Times. https://www.dermatologytimes.com/view/2023-innovations-garnering-gratitude. November 23, 2023.
12. Raj Chovatiya, MD, PhD: Reaction to Updated Guidelines for Generalized Pustular Psoriasis. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-phd-reaction-updated-guidelines-generalized-pustular-psoriasis. November 21, 2023.
13. Dupilumab-associated lymphoid reactions require caution. Dermatology News. https://www.mdedge.com/dermatology/article/266328/atopic-dermatitis/dupilumab-associated-lymphoid-reactions-require-caution. November 3, 2023.
14. What Does the FDA Approval of Secukinumab Mean for Patients with HS? HCPLive. https://www.hcplive.com/view/what-does-fda-approval-of-secukinumab-mean-for-patients-with-hs-. November 1, 2023.
15. Review finds no CV or VTE risk signal with use of JAK inhibitors for skin indications. Dermatology News. https://www.mdedge.com/dermatology/article/266268/atopic-dermatitis/review-finds-no-cv-or-vte-risk-signal-use-jak. November 1, 2023.
16. Dupilumab-Associated Lymphoid Reactions Require Caution. Medscape. https://www.medscape.com/viewarticle/997881. October 30, 2023.
17. Lebrikizumab Phase 3 Trials: ADvocate1 and ADvocate2 for Atopic Dermatitis. VuMedi. https://www.vumedi.com/video/lebrikizumab-phase-3-trials-advocate1-and-advocate2-for-atopic-dermatitis. October 26, 2023.
18. Empowering Patients: Navigating the Progression Risks of Actinic Keratosis and Optimizing Treatment Selection. HCPLive. https://www.hcplive.com/medcast-videos/taking-steps-to-shield-your-patients-from-pre-cancerous-changes-in-actinic-keratosis. October 24, 2023. 
19. 2023 Fall Clinical Dermatology Conference Highlights: What You Need To Know NOW About JAK Inhibitors. DermSquared. https://dermsquared.com/conference-highlights/fc23-daily-summary. October 21, 2023. 
20. JAK Inhibitors for the Treatment of Inflammatory Skin Diseases. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/derm/videos/jak-inhibitors-treatment-inflammatory-skin-diseases. October 20, 2023.
21. Type 2 inflammatory skin diseases – relieving itch: Raj Chovatiya, EADV 2023. touchDERMATOLOGY. https://touchderma.com/dermatitis/conference-hub/type-2-inflammatory-skin-diseases-relieving-itch-raj-chovatiya-eadv-2023. October 13, 2023.
22. 4 Common Household Products That Might Be Causing Your Eczema Flare-Ups. SELF. https://www.self.com/story/eczema-household-product-triggers. October 9, 2023.
23. Skyrizi achieves consistent results in plaque psoriasis across racial, ethnic groups. Healio. https://www.healio.com/news/dermatology/20231007/skyrizi-achieves-consistent-results-in-plaque-psoriasis-across-racial-ethnic-groups. October 7, 2023. 
24. Raj Chovatiya, MD, PhD: Utilizing Ruxolitinib Cream for Patients with Vitiligo. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-utilizing-ruxolitinib-cream-for-patients-with-vitiligo. October 4, 2023.
25. Editorial Advisory Board Insights for Eczema Awareness Month: Raj Chovatiya, MD, PhD. Dermatology Times. https://www.dermatologytimes.com/view/editorial-advisory-board-insights-for-eczema-awareness-month-raj-chovatiya-md-phd. October 1, 2023. 
26. Raj Chovatiya, MD, PhD: Atopic Dermatitis Update 2023. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-atopic-dermatitis-update-2023. September 29, 2023. 
27. Raj Chovatiya, MD, PhD: Safety of Oral JAK Inhibitors for Atopic Dermatitis. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-md-phd-safety-of-oral-jak-inhibitors-for-atopic-dermatitis. September 28, 2023. 
28. What to know about the addition of janus kinase inhibitors to the dermatologist’s armamentarium. touchDERMATOLOGY. https://touchderma.com/2023/09/28/what-to-know-about-the-addition-of-janus-kinase-inhibitors-to-the-dermatologists-armamentarium. September 28, 2023.
29. 4 For 4 Sessions With Raj Chovatiya, MD, PhD, Present Range of Dermatology Challenges and Opportunities. https://www.dermatologytimes.com/view/4-for-4-sessions-with-raj-chovatiya-md-phd-present-range-of-dermatology-challenges-and-opportunities. Dermatology Times. September 27, 2023. 
30. Biosimilars in Psoriasis: The Future of Treatment. https://reachmd.com/programs/dermconsult/biosimilars-in-psoriasis-the-future-of-treatment/15951. ReachMD. September 12, 2023.
31. Treating Atopic Dermatitis: A Look at the Current & Future Landscape. https://reachmd.com/programs/dermconsult/treating-atopic-dermatitis-a-look-at-the-current-future-landscape/15595. ReachMD. September 7, 2023.
32. Applying Shared Decision-Making to Atopic Dermatitis Care. https://reachmd.com/programs/dermconsult/applying-shared-decision-making-to-atopic-dermatitis-care/15596. ReachMD. September 7, 2023.
33. Psoriasis Treatment Redefined: Exploring the Impact of IL-23 Inhibitors. https://reachmd.com/programs/dermconsult/psoriasis-treatment-redefined-exploring-the-impact-of-il-23-inhibitors/15836. ReachMD. September 5, 2023.
34. From Pathophysiology to Therapeutic Progress: TYK2's Significance in Plaque Psoriasis. https://reachmd.com/programs/dermconsult/from-pathophysiology-to-therapeutic-progress-tyk2s-significance-in-plaque-psoriasis/15835.  ReachMD. September 5, 2023
35. Unmet Needs in Seborrheic Dermatitis. https://practicaldermatology.com/expert-highlights/arcutis/unmet-needs-in-seborrheic-dermatitis. Practical Dermatology. August 29, 2023.
36. A New Era in Plaque Psoriasis Care: Examining Topical Nonsteroidal Therapies. https://reachmd.com/programs/dermconsult/a-new-era-in-plaque-psoriasis-care-examining-topical-nonsteroidal-therapies/15834. ReachMD. August 25, 2023.
37. Breakthroughs in Generalized Pustular Psoriasis Treatment: Exploring Current & Emerging Approaches. ReachMD. https://reachmd.com/programs/dermconsult/breakthroughs-in-generalized-pustular-psoriasis-treatment-exploring-current-emerging-approaches/15833.  August 25, 2023.
38. Raj Chovatiya, MD, PhD: Repigmentation of Vitiligo Using Topical Therapies. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-itch-in-atopic-dermatitis. August 8, 2023.
39. World Congress of Dermatology 2023: Spotlighting Leaders in Derm. Dermatology Times. https://www.dermatologytimes.com/view/world-congress-of-dermatology-2023-spotlighting-leaders-in-derm. August 7, 2023.
40. Eczema Answered: “How can I use light therapy to treat my eczema at home?” — Dr. Raj Chovatiya. National Eczema Association. https://nationaleczema.org/blog/eczema-answered-phototherapy. August 7, 2023.
41. Improving Treatment Adherence in Atopic Dermatitis. Medpage Today. https://www.medpagetoday.com/medical-journeys/atopic-dermatitis/105748. August 7, 2023 
42. What factors cause multiple biologic failure in psoriasis? Medscape. https://www.medscape.com/s/viewarticle/995148.  August 3, 2023.
43. What factors cause multiple biologic failure in psoriasis? Dermatology News. https://www.mdedge.com/dermatology/article/264487/psoriasis/what-factors-cause-multiple-biologic-failure-psoriasis. August 2, 2023.
44. Can ruxolitinib cream be used in combination with therapeutic biologics, other JAK inhibitors, or immunosuppressants? Dermbits. https://dermsquared.com/videos/dermbits/can-ruxolitinib-used-combination-with-therapeutic-biologics-jak-inhibitors-immunosuppressants. August 1, 2023.
45. What limitations of other atopic dermatitis therapies does ruxolitinib cream address? Dermbits. https://dermsquared.com/videos/dermbits/limitations-other-atopic-dermatitis-therapies-ruxolitinib-address. August 1, 2023.
46. How quickly can patients expect to start feeling itch reduction with ruxolitinib cream? Dermbits. https://dermsquared.com/videos/dermbits/how-quickly-expect-itch-reduction-with-ruxolitinib-cream. August 1, 2023.
47. Ruxolitinib cream is indicated for short-term use; when should patients discontinue use?Dermbits. https://dermsquared.com/videos/dermbits/ruxolitinib-cream-is-indicated-for-short-term-use-when-should-patients-discontinue-use. August 1, 2023.
48. What is the recommended dosing regimen for ruxolitinib cream? Dermbits. https://dermsquared.com/videos/dermbits/what-is-the-recommended-dosing-regimen-for-ruxolitinib-cream. August 1, 2023.
49. What is the maximum dosage per week recommended for ruxolitinib cream? Dermbits. https://dermsquared.com/videos/dermbits/maximum-dosage-per-week-recommended-for-ruxolitinib-cream. August 1, 2023.
50. When do you recommend the use of wet wrap therapy for patients with atopic dermatitis experiencing a flare? Dermbits. https://dermsquared.com/videos/dermbits/when-recommend-wet-wrap-therapy-with-atopic-dermatitis-flare. August 1, 2023.
51. When should oral antibiotics be used in the treatment of atopic dermatitis? Dermbits. https://dermsquared.com/videos/dermbits/when-should-oral-antibiotics-be-used-in-the-treatment-of-atopic-dermatitis. August 1, 2023.
52. What do you recommend for patients with atopic dermatitis who require long-term treatment? Dermbits. https://dermsquared.com/videos/dermbits/what-recommend-patients-atopic-dermatitis-who-require-long-term-treatment. August 1, 2023.
53. Kidney Disease-Associated Pruritus and Managing Prurigo Nodularis: Treatment Pearls From Raj Chovatiya, MD, PhD. https://www.dermatologytimes.com/view/kidney-disease-associated-pruritis-and-managing-prurigo-nodularis-treatment-pearls-from-raj-chovatiya-md-phd. July 7, 2023. 
54. Achieving Durable Clinical Response with Targeted Treatments for Vitiligo. HCPLive. https://www.hcplive.com/medcast-videos/achieving-durable-clinical-response-with-targeted-treatments-for-vitiligo. July 5, 2023. 
55. Expert Providers Share Their Thoughts on Artificial Intelligence in Dermatology. Dermatology Times. https://www.dermatologytimes.com/view/expert-providers-share-their-thoughts-on-artificial-intelligence-in-dermatology. June 28, 2023. 
56. Advising Patients on Atopic Dermatitis Treatment Options: Expert Pearls. Medscape. https://www.medscape.com/s/viewarticle/993315. June 16, 2023.
57. Advising patients on AD treatment options: Expert pearls. Dermatology News. https://www.mdedge.com/dermatology/article/263508/atopic-dermatitis/advising-patients-ad-treatment-options-expert-pearls. June 12, 2023.
58. Reviewing New Therapies for Hidradenitis Suppurativa. ReachMD. https://reachmd.com/programs/dermconsult/reviewing-new-therapies-for-hidradenitis-suppurative/15262. May 22, 2023
59. B-VEC Approved for the Treatment of Dystrophic Epidermolysis Bullosa. Dermatology Times. https://www.dermatologytimes.com/view/b-vec-approved-for-the-treatment-of-dystrophic-epidermolysis-bullosa. May 19, 2023. 
60. FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older. Contemporary Pediatrics. https://www.contemporarypediatrics.com/view/fda-approves-b-vec-to-treat-dystrophic-epidermolysis-bullosa-patients-6-months-and-older. May 19, 2023. 
61. Investigating Hidradenitis Suppurativa: A Multifactorial Disease. ReachMD. https://reachmd.com/programs/dermconsult/investigating-hidradenitis-suppurativa-a-multifactorial-disease/15261. May 12, 2023
62. Managing Vitiligo in 2023: New Therapies, Emerging Data, Pediatric Indications. HCPLive. https://www.hcplive.com/view/managing-vitiligo-in-2023-new-therapies-emerging-data-pediatric-indications. May 11, 2023. 
63. You Don’t Know JAK: The Promise of New Therapies for Skin Disease with Dr. Raj Chovatiya. The Skin Real. https://podcasts.apple.com/us/podcast/you-dont-know-jak-the-promise-of-new-therapies-for/id1638619358?i=1000612138613. May 8, 2023. 
64. Rad Quotes from RAD 2023. Dermatology Times. https://www.dermatologytimes.com/view/rad-quotes-from-rad-2023. May 4, 2023. 
65. Raj Chovatiya, MD, PhD: Long-Term Control of Atopic Dermatitis with Current Therapies. HCPLive. https://www.hcplive.com/view/raj-chovatiya-long-term-control-atopic-dermatitis-current-therapies. May 4, 2023.
66. Raj Chovatiya, MD, PhD: Tapinarof Cream in Adolescents, Children with Atopic Dermatitis. HCPLive. https://www.hcplive.com/view/raj-chovatiya-tapinarof-cream-adolescents-children-atopic-dermatitis. May 4, 2023.
67. Upadacitinib, Long-Term Control, and Tapinarof, Oh My! Dermatology Times. https://www.dermatologytimes.com/view/upadacitinib-long-term-control-and-tapinarof-oh-my-. May 2, 2023. 
68. Previewing RAD 2023 With Raj Chovatiya, MD, PhD. Dermatology Times. https://www.dermatologytimes.com/view/previewing-rad-2023-with-raj-chovatiya-md-phd. April 30, 2023.
69. Identifying Rare Dermatologic Disorders in the Critical Care Setting. HCPLive. https://www.hcplive.com/peer-exchange/identifying-rare-dermatologic-disorders-in-the-critical-care-setting. April 29. 2023. 
70. Why You Have Pimples on Your Balls—and How to Get Rid of Them. Men’s Health. https://www.menshealth.com/health/a25359856/pimple-on-balls. April 27, 2023.
71. Dr Raj Chovatiya on Optimizing Patient-Centered Care in Atopic Dermatitis. American Journal of Managed Care (AJMC). https://www.ajmc.com/view/dr-raj-chovatiya-on-optimizing-patient-centered-care-in-atopic-dermatitis. April 25, 2023.
72. Starting Baricitinib Early for Severe Alopecia Areata Beneficial. My Best Medicine. https://mybestmedicine.com/health-news/starting-baricitinib-early-for-severe-alopecia-areata-beneficial. April 12, 2023. 
73. The earlier baricitinib for severe alopecia areata is started, the better. Dermatology News. https://www.mdedge.com/dermatology/article/262318/hair-nails/earlier-baricitinib-severe-alopecia-areata-started-better. April 11, 2023. 
74. When it looks and itches like atopic dermatitis. But isn’t. AAD DermWorld. https://www.aadmeetingnews.org/aad-2023-annual-meeting/article/22806835/when-it-looks-and-itches-like-atopic-dermatitis-but-isnt. April 7, 2023.
75. Raj Chovatiya, Dermatology Meeting News 2023: JAK inhibitor treatment & monitoring guidelines in inflammatory dermatologic diseases. touchIMMUNOLOGY. https://www.touchimmunology.com/dermatological-conditions/conference-hub/raj-chovatiya-dermatology-meeting-news-2023-jak-inhibitor-treatment-monitoring-guidelines-in-inflammatory-dermatologic-diseases. April 5, 2023. 
76. Raj Chovatiya, Dermatology Meeting News 2023: Efficacy & safety profile of baricitinib for inflammatory dermatologic disease. touchIMMUNOLOGY. https://www.touchimmunology.com/dermatological-conditions/conference-hub/raj-chovatiya-dermatology-meeting-news-2023-efficacy-safety-profile-of-baricitinib-for-inflammatory-dermatologic-disease. April 5, 2023. 
77. Exploring Emerging Therapies for Alopecia Areata. ReachMD. https://reachmd.com/programs/dermconsult/exploring-emerging-therapies-for-alopecia-areata/15099. April 4, 2023
78. Alopecia Areata: Exploring New Data. ReachMD. https://reachmd.com/programs/dermconsult/alopecia-areata-exploring-new-data/15098. April 4, 2023
79. Recent Advances in the Treatment of Alopecia Areata. HCPLive. https://www.hcplive.com/medcast-videos/recent-advances-in-the-treatment-of-alopecia-areata. April 3, 2023. 
80. Rapid Pruritus Reduction with Ruxolitinib Cream Treatment in Patients with Atopic Dermatitis. Dermatology Times. https://www.dermatologytimes.com/between-the-lines/rapid-pruritus-reduction-with-ruxolitinib-cream-treatment-in-patients-with-atopic-dermatitis. March 31, 2023.
81. Raj Chovatiya, MD, PhD: Itch in Atopic Dermatitis. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-itch-in-atopic-dermatitis. March 28, 2023.
82. Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows. Dermatology News. https://www.mdedge.com/dermatology/article/262057/atopic-dermatitis/topical-delgocitinib-shows-promise-chronic-hand-eczema. March 27, 2023.
83. Expert Perspectives on Generalized Pustular Psoriasis. Dermatology Times. https://www.dermatologytimes.com/expert-perspectives/expert-perspectives-on-generalized-pustular-psoriasis. March 24, 2023. 
84. How to Cope With the Hidden Mental Health Effects of Eczema. SELF. https://www.self.com/story/eczema-mental-health-help. March 23, 2023. 
85. Raj Chovatiya, MD, PhD: Highlights from Presentation on JAK Inhibitors. HCPLive. https://www.hcplive.com/view/raj-chovatiya-highlights-presentation-jak-inhibitors. March 22, 2023.
86. Raj Chovatiya, MD, PhD, Discusses All Things Inflammatory Diseases at AAD 2023. Dermatology Times. https://www.dermatologytimes.com/view/raj-chovatiya-md-phd-discusses-all-things-inflammatory-diseases-at-aad-2023. March 20, 2023. 
87. CSU in children: Study identifies biomarkers associated with responses to different treatments. Dermatology News. https://www.mdedge.com/dermatology/article/261871/urticaria/csu-children-study-identifies-biomarkers-associated-responses. March 19, 2023.
88. Raj Chovatiya, MD, PhD: Itch Tales. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-aad-2023. March 19, 2023.
89. AAD 2023 Live Coverage: Hidradenitis Suppurativa and Psoriasis. HCPLive. https://twitter.com/MDMagazine/status/1636727220625391616. March 17, 2023.
90. AAD 2023 Live Coverage: Alopecia Areata and Vitiligo. HCPLive. https://www.linkedin.com/posts/hcplive_alopecia-vitiligo-aad2023-activity-7042494629459415041-3WxZ. March 17, 2023.
91. Management of Atopic Dermatitis in Pediatric and Adult Patients. HCPLive. https://www.hcplive.com/medcast-videos/management-of-atopic-dermatitis-in-pediatric-and-adult-patients. March 14, 2023. 
92. Skin in the Game: How Shared Decision-Making is the Difference | Episode 2 pt 2. UCB Elevate Podcast. https://youtu.be/QoTggfrcktk. March 13, 2023.
93. Skin in the Game: How Shared Decision-Making is the Difference | Episode 2 pt 1. UCB Elevate Podcast. https://youtu.be/GUHGRktNwhQ. March 13, 2023.
94. Atopic Dermatitis: The Latest on Diagnosis and Assessment. Medpage Today. https://www.medpagetoday.com/medical-journeys/atopic-dermatitis/103350. March 3, 2023 
95. Eczema Out Loud: Phototherapy for Eczema – Dr. Raj Chovatiya. National Eczema Association. https://nationaleczema.org/blog/podcast-phototherapy. March 1, 2023 
96. Raj Chovatiya, MD, PhD: Alopecia Areata Patient Needs, Black Box Warnings for JAK Inhibitors. HCPLive. https://www.hcplive.com/view/raj-chovatiya-alopecia-areata-black-box-warnings-jak-inhibitors. February 22, 2023.
97. Raj Chovatiya, MD, PhD: JAK Inhibitor Breakthroughs for Alopecia Areata. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-jak-inhibitor-breakthroughs-alopecia-areata. February 22, 2023.
98. Raj Chovatiya, MD, PhD: The Evolution of Treatment for Alopecia Areata. Dermatology Times. https://www.dermatologytimes.com/view/raj-chovatiya-md-phd-evolution-treatment-alopecia-areata. February 19, 2023. 
99. New Jak Inhibitors for the Treatment of Alopecia Areata. FC TV. https://youtu.be/YByaBjfhpEg. February 18, 2023. 
100. HS Treatment Response Rates Continue to Improve with Secukinumab at Week 52. Dermatology Times. https://www.dermatologytimes.com/view/hs-treatment-response-rates-continue-to-improve-with-secukinumab-at-week-52. February 3, 2023.
101. First Adalimumab Biosimilar, Adalimumab-atto, Available in the US. Dermatology Times. https://www.dermatologytimes.com/view/first-adalimumab-biosimilar-adalimumab-atto-available-in-the-us. January 31, 2023. 
102. Raj Chovatiya, MD, PhD: Exceptional Eczematous Expertise. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/chovatiya-maui-derm-2023-eczema. January 28, 2022.
103. Personalizing Treatment Selection in Atopic Dermatitis. HCPLive. https://www.hcplive.com/peer-exchange/personalizing-treatment-selection-in-atopic-dermatitis. January 26, 2023.
104. Raj Chovatiya, MD, PhD: Comparing Abrocitinib to Other Treatments for Atopic Dermatitis. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-phd-comparing-abrocitinib-treatments-atopic-dermatitis. January 16, 2023.
105. Raj Chovatiya, MD, PhD: Winter Clinical Highlights on Atopic Dermatitis, Abrocitinib. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-phd-winter-clinical-highlights-atopic-dermatitis-abrocitinib. January 15, 2023.
106. Raj Chovatiya, MD, PhD, Shares What He is Looking Forward to at Winter Clinical Hawaii. Dermatology Times. https://www.dermatologytimes.com/view/raj-chovatiya-md-phd-shares-what-he-is-looking-forward-to-at-winter-clinical-hawaii. January 13, 2023
107. Latest Advances in the Management of Atopic Dermatitis. HCPLive. https://www.hcplive.com/view/latest-advances-in-the-management-of-atopic-dermatitis. December 22, 2022.
108. Latest Advances in the Management of Vitiligo. HCPLive. https://www.hcplive.com/view/latest-advances-in-the-management-of-vitiligo. December 22, 2022.
109. A Conversation About JAK Inhibitors in Atopic Dermatitis. Dermatology Times. https://www.dermatologytimes.com/view/a-conversation-about-jak-inhibitors-in-atopic-dermatitis. December 19, 2022.
110. JAK Inhibitors in the Management of Atopic Dermatitis. Dermatology Times. https://www.dermatologytimes.com/frontline-forum/jak-inhibitors-in-the-management-of-atopic-dermatitis. December 14, 2022.
111. Challenging Cases in Atopic Dermatitis. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/podcasts/challenging-cases-atopic-dermatitis. December 13, 2022.
112. Raj Chovatiya, MD, PhD, Discusses his Sessions at the Upcoming RAD Conference. Dermatology Times. https://www.dermatologytimes.com/view/raj-chovatiya-md-phd-discusses-his-sessions-at-the-upcoming-rad-conferenc. December 10, 2022.
113. Advances in the Management of Prurigo Nodularis. HCPLive. https://www.hcplive.com/peer-exchange/advances-in-the-management-of-prurigo-nodularis. December 10, 2022. 
114. Pooled Safety of Tralokinumab Reported. Dermatology News. https://www.mdedge.com/dermatology/article/260001/atopic-dermatitis/pooled-safety-data-analysis-tralokinumab-reported. December 8, 2022.
115. Challenging Cases in Atopic Dermatitis. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/challenging-cases-atopic-dermatitis. December 7, 2022.
116. Raj Chovatiya, MD, PhD: Psoriasis Treatment Developments, FDA Approvals in 2022. https://www.hcplive.com/view/raj-chovatiya-md-phd-psoriasis-treatment-developments-fda-approvals-2022. December 7, 2022.
117. Seborrheic Dermatitis: Unmet Needs and Innovations. The Dermatology Digest. https://thedermdigest.com/video/seborrheic-dermatitis-unmet-needs-and-innovations. December 1, 2022.
118. Innovations in Topical Treatments for Pruritic Medical Conditions. The Dermatology Digest. https://thedermdigest.com/video/the-role-of-vehicle-formulation-in-topical-therapy-for-inflammatory-skin-diseases. December 1, 2022. 
119. The Role of Vehicle Formulation in Topical Therapy for Inflammatory Skin Diseases. The Dermatology Digest. https://thedermdigest.com/video/innovations-in-topical-treatments-for-pruritic-medical-conditions. December 1, 2022. 
120. A Look at the Evolving Therapeutic Landscape for Vitiligo. ReachMD. https://reachmd.com/programs/dermconsult/a-look-at-the-evolving-therapeutic-landscape-for-vitiligo/14415. November 27, 2022.
121. Lack of Diagnosis Efficiency in Adults With Seborrheic Dermatitis. VuMedi. https://www.vumedi.com/video/lack-of-diagnosis-efficiency-in-adults-with-seborrheic-dermatitis. November 11, 2022.
122. Positive New Results of Tapinarof Cream Study for Pediatric Patients with AD. Dermatology Times. https://www.dermatologytimes.com/view/positive-new-results-of-tapinarof-cream-study-for-pediatric-patients-with-ad. November 11, 2022.
123. A Conversation About JAK Inhibitors in Atopic Dermatitis. Dermatology Times. https://www.dermatologytimes.com/view/a-changing-treatment-landscape-in-atopic-dermatitis. November 1, 2022.
124. Nationwide seborrheic dermatitis survey reveals ‘large educational gap to overcome’. Healo. https://www.healio.com/news/dermatology/20221101/nationwide-seborrheic-dermatitis-survey-reveals-large-educational-gap-to-overcome. November 1, 2022.
125. What is the overall safety and tolerability profile for topical roflumilast? Dermbits. https://fallclinical.health/dermbits-what-is-the-overall-safety-and-tolerability-profile-for-topical-roflumilast-arcp22. October 28, 2022
126. Can topical roflumilast replace topical corticosteroids, or are they meant to be used in tandem? Dermbits. https://fallclinical.health/dermbits-can-topical-roflumilast-replace-topical-corticosteroids-or-are-they-meant-to-be-used-in-tandem-arcp22. October 28, 2022
127. Can topical roflumilast be used for younger patients? Dermbits. https://fallclinical.health/dermbits-can-topical-roflumilast-be-used-for-younger-patients-arcp22. October 28, 2022
128. Is topical roflumilast safe for long-term use? Dermbits. https://fallclinical.health/dermbits-is-topical-roflumilast-safe-for-long-term-use-arcp22. October 28, 2022
129. Do you augment oral and/or biologic therapy with a topical? Dermbits. https://fallclinical.health/dermbits-do-you-augment-oral-andor-biologic-therapy-with-a-topical-arcp22. October 28, 2022
130. How do you determine if a patient is a better candidate for topical treatment vs. an oral or biologic? Dermbits. https://fallclinical.health/dermbits-how-do-you-determine-patient-better-candidate-for-topical-treatment-vs-an-oral-or-biologic-arcp22. October 28, 2022
131. Which patients may benefit the most from topical roflumilast? Dermbits. https://fallclinical.health/dermbits-which-patients-may-benefit-the-most-from-topical-roflumilast-arcp22. October 28, 2022
132. How effective is topical roflumilast at treating sensitive areas like the face, genitalia, and intertriginous psoriasis areas? Dermbits. https://fallclinical.health/dermbits-how-effective-is-topical-roflumilast-at-treating-sensitive-areas-face-genitalia-and-intertriginous-psoriasis-areas-arcp22. October 28, 2022
133. What is the mechanism of action of topical roflumilast and how is it different than other PDE4 inhibitors? Dermbits. https://fallclinical.health/dermbits-what-is-the-mechanism-of-action-of-topical-roflumilast-and-how-is-it-different-than-other-pde4-inhibitors-arcp22. October 28, 2022
134. What excites you most about the approval of topical roflumilast? Dermbits. https://fallclinical.health/dermbits-what-excites-you-most-about-the-approval-of-topical-roflumilast-arcp22. October 28, 2022
135. Dermatology Pearls. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/conference-coverage/dermatology-pearls. October 24, 2022.
136. Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis. Arcutis Biotherapeutics. https://www.arcutis.com/nationwide-seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis. October 21, 2022.
137. How Do Chronic Urticaria Patients Fare with Pregnancy. Dermatology News. https://www.mdedge.com/dermatology/article/258561/medical-dermatology/how-do-patients-chronic-urticaria-fare-during. October 11, 2022.
138. Roflumilast for Treatment of Plaque Psoriasis: DERMIS-1 and DERMIS-2 Randomized Phase 3 Clinical Trials Review. VuMedi. https://www.vumedi.com/video/roflumilast-for-treatment-of-plaque-psoriasis-dermis-1-and-dermis-2-randomized-phase-3-clinical-tria/. October 6, 2022.
139. Raj Chovatiya, MD, PhD, Gets Excited About Presenting at Fall Clinical 2022. Dermatology Times. https://www.dermatologytimes.com/view/raj-chovatiya-md-phd-gets-excited-about-presenting-at-fall-clinical-2022. October 6, 2022.
140. Recognizing & Addressing the Burden of Vitiligo. ReachMD. https://reachmd.com/programs/dermconsult/recognizing-addressing-the-burden-of-vitiligo/13974. September 16, 2022.
141. New Approaches to Treating Vitiligo: The Emerging Role of JAK Inhibitors. ReachMD. https://reachmd.com/programs/dermconsult/new-approaches-to-treating-vitiligo-the-emerging-role-of-jak-inhibitors/13977. September 16, 2022.
142. Deucravacitinib Approved by FDA for Treatment of Psoriasis. Dermatology Times. https://www.dermatologytimes.com/view/deucravacitinib-approved-by-fda-for-treatment-of-psoriasis. September 10, 2022.
143. Atopic Dermatitis: The Patient Journey. Contemporary Pediatrics. https://www.contemporarypediatrics.com/cure-connections/atopic-dermatitis-the-patient-journey. August 25, 2022
144. Expert Perspectives in the Management of Pediatric Atopic Dermatitis. Contemporary Pediatrics. https://www.contemporarypediatrics.com/peer-exchange/expert-perspectives-in-the-management-of-pediatric-atopic-dermatitis. Auguat 24, 2022.
145. Retirement Planning. LEAD Project. https://projectlead.health/professional-dev/retirement-planning. August 23, 2022.
146. Getting to the Roots of Childhood Atopic Dermatitis. Contemporary Pediatrics. https://www.contemporarypediatrics.com/around-the-practice/getting-into-the-roots-of-childhood-atopic-dermatitis. August 18, 2022 
147. Getting to the Roots of Childhood Atopic Dermatitis. Dermatology Times. https://www.dermatologytimes.com/around-the-practice/getting-into-the-roots-of-childhood-atopic-dermatitis. August 11, 2022.
148. Dermatologists Share Vitiligo Breakthrough News With Patients. Medscape. https://www.medscape.com/viewarticle/978705. August 5, 2022.
149. FDA Approves Roflumilast Cream for Adolescent, Adult Plaque Psoriasis. HCPLive. https://www.hcplive.com/view/fda-approves-roflumilast-cream-adolescent-adult-plaque-psoriasis.July 29, 2022.
150. Expert Perspectives in the Management of Pediatric Atopic Dermatitis. HCPLive. https://www.hcplive.com/peer-exchange/expert-perspectives-in-the-management-of-pediatric-atopic-dermatitis. July 29, 2022.
151. Wellbeing Checkup: When it’s Time to Say No. Medical World News. https://www.medicalworldnews.com/view/wellbeing-checkup-when-its-time-to-say-no. July 26, 2022.
152. FDA Approves Ruxolitinib Cream 1.5% for Nonsegmental Vitiligo. HCPLive. https://www.hcplive.com/view/fda-approves-ruxolitinib-cream-for-nonsegmental-vitiligo. July 18, 2022.
153. The Cutaneous Connection: Advancements in Atopic Dermatitis Treatment. Dermatology Times. https://www.dermatologytimes.com/view/the-cutaneous-connection-advancements-in-atopic-dermatitis-treatment. July 12, 2022.
154. Eczema causes substantial burden for many infants and preschoolers. Dermatology News. https://www.mdedge.com/dermatology/article/256191/atopic-dermatitis/eczema-causes-substantial-burden-many-infants-and. July 11, 2022.
155. Eczema severity, time spent on management strongly associated with overall disease burden. Dermatology News. https://www.mdedge.com/dermatology/article/256123/atopic-dermatitis/eczema-severity-time-spent-management-strongly. July 8, 2022.
156. Itch and Psoriasis. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-itch-psoriasis. June 28, 2022.
157. Therapeutic Possibilities for Vitiligo. HCPLive. https://www.hcplive.com/view/chovatiya-md-phd-therapeutic-possibilities-vitiligo. June 23, 2022.
158. Addressing Social Determinants of Health to Improve Care for Patients With Atopic Dermatitis. First Report Managed Care. https://www.hmpgloballearningnetwork.com/site/frmc/podcasts/addressing-social-determinants-health-improve-care-patients-atopic-dermatitis. June 23, 2022.
159. Clinical Conversations: The Data for JAK Inhibitors in AD. Practical Dermatology. https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-the-data-for-jak-inhibitors-in-ad. June 20, 2022
160. Reviewing Atopic Dermatitis Prevalence, Disease Severity's Impact on Patients. First Report Managed Care. https://www.hmpgloballearningnetwork.com/site/frmc/podcasts/reviewing-atopic-dermatitis-prevalence-disease-severitys-impact-patients. June 16, 2022.
161. The Clinical Burden of AD and the JAK-STAT Pathway. The Dermatologist https://www.hmpgloballearningnetwork.com/site/thederm/clinical-insights/clinical-burden-ad-and-jak-stat-pathway. June 12, 2022.
162. Explaining the Mechanisms and Advantages of JAK Inhibitors. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/raj-chovatiya-explaining-mechanisms-advantages-jak-inhibitors. June 9, 2022.
163. Patients with seborrheic dermatitis dissatisfied with treatment options. Healio Dermatology. https://www.healio.com/news/dermatology/20220601/patients-with-seborrheic-dermatitis-dissatisfied-with-treatment-options. June 1, 2022.
164. JAK Inhibitors, Monoclonal Antibodies, Corticosteroids: Choosing a Treatment for Atopic Dermatitis. First Report Managed Care. https://www.hmpgloballearningnetwork.com/site/frmc/interview/jak-inhibitors-monoclonal-antibodies-corticosteroids-choosing-treatment-atopic. May 25, 2022
165. Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care. Arcutis Biotherapeutics, Inc. https://www.arcutis.com/nationwide-survey-of-people-with-seborrehic-dermatitis-reveals-dissatisfaction-with-current-treatment-options-and-burden-of-daily-care. May 25, 2022
166. Clinical Conversations: MOA of JAK Inhibitors in Dermatology. Practical Dermatology. https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology. May 23, 2022
167. Atopic Dermatitis: The Patient Journey. HCPLive. https://www.hcplive.com/peer-exchange/atopic-dermatitis-the-patient-journey. May 17, 2022
168. JAK inhibitors for the management of atopic dermatitis (AD). HCPLive. https://www.hcplive.com/peer-exchange/jak-inhibitors-for-the-management-of-atopic-dermatitis-ad. April 27, 2022
169. Skin pain and inflammatory disease. The Dermatology Digest. https://thedermdigest.com/video/skin-pain-and-inflammatory-skin-disease. April 8, 2022.
170. The many potential uses of dupilumab. The Dermatology Digest. https://thedermdigest.com/podcast/the-many-potential-uses-of-dupilumab. April 8, 2022.
171. Detailing potential dermatology drug approvals from AAD 2022. HCPLive. https://www.hcplive.com/view/detailing-potential-dermatology-drug-approvals-from-aad-2022. March 27, 2022.
172. Financial Burdens of Polypharmacy Among Patients with Atopic Dermatitis. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/chovatiya-aad2022-atopic-dermatitis. March 27, 2022.
173. Discussing atopic dermatitis treatment risks with patients. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/atopic-dermatitis-advisor. March 8, 2022.
174. What does a black box warning mean for eczema treatments? National Eczema Association. https://nationaleczema.org/black-box-warning-eczema. February 28, 2022.
175. Mechanisms of atopic dermatitis therapies. Journal of Clinical and Aesthetic Dermatology (JCAD) TV. https://jcad.tv/atopic-dermatitis-advisor. February 22, 2022.
176. Broadening clinical research and education for skin of color. HCPLive. https://www.hcplive.com/view/chovatiya-md-phd-broadening-clinical-research-education-skin-of-color. February 16, 2022.
177. Impact of Out-of-Pocket Expenses for Atopic Dermatitis. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/impact-out-pocket-expenses-atopic-dermatitis. February 13, 2022.
178. More frequent secukinumab dosing found to benefit overweight psoriasis patients. Rheumatology News. https://www.mdedge.com/rheumatology/article/251179/psoriasis/more-frequent-secukinumab-dosing-found-benefit-overweight. January 26, 2022.
179. Longitudinal course of atopic dermatitis often overlooked, expert says. Medscape. https://www.medscape.com/viewarticle/966160. January 6, 2022.
180. AD burden may be greater for those with head, neck, face, and hand involvement. Dermatology News. https://www.mdedge.com/dermatology/article/250213/atopic-dermatitis/ad-burden-may-be-greater-those-head-neck-face-and-hand. December 23, 2021.
181. Abrocitinib efficacy dose-dependent, similar across AD age groups. Dermatology News. https://www.mdedge.com/dermatology/article/249968/atopic-dermatitis/abrocitinib-efficacy-dose-dependent-similar-across-ad. December 15, 2021.
182. Detailing racial disparities in dermatology at health care crossroad. HCPLive. https://www.hcplive.com/view/detailing-racial-disparities-dermatology-health-care-crossroad. December 15, 2021.
183. The promise of UV light therapy for patients with vitiligo. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-phd-vitiligo-research-treatment. December 6, 2021.
184. Patient-reported outcomes to support AD care. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/videos/patient-reported-outcomes-support-ad-care. October 20, 2021.
185. Confronting issues and challenges beneath the surface: technology and data analytics. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/confronting-issues-and-challenges-beneath-surface-technology-and. October 14, 2021
186. AD and out of pocket health care expenses. Dermatology Times. https://www.dermatologytimes.com/view/study-ad-and-out-of-pocket-health-care-expenses. October 11, 2021.
187. New study shows: black americans face higher out-of-pocket costs related to atopic dermatitis. National Eczema Association. https://nationaleczema.org/black-americans-and-eczema-costs. October 1, 2021.
188. Advances in the management of atopic dermatitis. HCPLive. https://www.hcplive.com/peer-exchange/advances-in-the-management-of-atopic-dermatitis. September 29, 2021
189. New frontiers open for AD, eczema solutions. Dermatology Times. https://www.dermatologytimes.com/view/new-frontiers-open-for-ad-eczema-solutions. September 23, 2021.
190. The worse it gets, the more we spend: new findings show atopic dermatitis out of pocket costs tied to severity of the disease. National Eczema Association. https://nationaleczema.org/out-of-pocket-severity. September 13, 2021.
191. Expanding on vitiligo research. HCPLive. https://www.hcplive.com/view/raj-chovatiya-md-phd-vitiligo-research-treatment. September 10, 2021.
192. Defining iatrogenic burdens in atopic dermatitis. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/nea-approved-features/defining-iatrogenic-burdens-atopic-dermatitis. September 3, 2021
193. Treatment burden and quality of life in atopic dermatitis. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/videos/treatment-burden-and-quality-life-atopic-dermatitis. August 30, 2021.
194. Atopic dermatitis in skin of color. VuMedi. https://www.vumedi.com/video/atopic-dermatitis-in-skin-of-color-terminology-epidemiology-pathophysiology-clinical-presentation-an. August 18, 2021.
195. Minimizing iatrogenic burden of atopic dermatitis. AAD DermWorld. https://www.aadmeetingnews.org/previews/article/21551404/minimizing-iatrogenic-burden-of-atopic-dermatitis. July 7, 2021
196. Secrets of effective research. AAD DermWorld Directions in Residency. https://assets.ctfassets.net/1ny4yoiyrqia/3eARfmyr4OK2lasucfLf0S/70bdf9dfe0d8ccc9e7a776418b8bbd2b/DIR_Summer_2021.pdf. Summer 2021.
197. Survey spotlights the out-of-pocket burden on Blacks with atopic dermatitis. Dermatology News. https://www.mdedge.com/dermatology/article/242177/atopic-dermatitis/survey-spotlights-out-pocket-burden-blacks-atopic. June 25, 2021.
198. The impact of air pollution on eczema. HealthCentral. https://www.healthcentral.com/article/eczema-and-air-pollution. June 8, 2021.
199. AD Phenotypes: Treatment and Utilization. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/news/ad-phenotypes-treatment-and-utilization. April 29, 2021.
200. AD Phenotypes: Itch and Lesional Severity. The Dermatologist. https://www.hmpgloballearningnetwork.com/site/thederm/news/ad-phenotypes-itch-and-lesional-severity. April 29, 2021.
201. New Research Reveals Out-Of-Pocket Cost Of Eczema. PR Newswire. https://www.prnewswire.com/news-releases/new-research-reveals-out-of-pocket-cost-of-eczema-301219736.html. February 2, 2021.
202. Chronic Inflammatory Skin Diseases Associated with Hospitalization for Herpes Zoster. DermatologyAdvisor. https://www.dermatologyadvisor.com/home/topics/general-dermatology/chronic-inflammatory-skin-diseases-associated-with-hospitalization-for-herpes-zoster. July 15, 2020.
203. Inflammatory skin diseases may be associated with herpes zoster hospitalization risk. Healio Dermatology. https://www.healio.com/news/dermatology/20200622/inflammatory-skin-diseases-may-be-associated-with-herpes-zoster-hospitalization-risk. June 22, 2020.
204. 2019 dermMentors™ Resident of Distinction Award™. Dermatology News. https://www.mdedge.com/dermatology/article/209800/2019-dermmentorstm-resident-distinction-awardtm. October 9, 2019.
205. Measles complications in the U.S. unchanged in posteradication era. ClinicalEdge. https://www.mdedge.com/dermatology/article/200997/infectious-diseases/measles-complications-us-unchanged-posteradication. May 15, 2019.
206. Measles complications in the U.S. unchanged in posteradication era. Dermatology News. https://www.mdedge.com/dermatology/article/200997/infectious-diseases/measles-complications-us-unchanged-posteradication. May 15, 2019.
207. Measles complications in the U.S. unchanged in posteradication era. The Hospitalist. https://www.the-hospitalist.org/hospitalist/article/200997/infectious-diseases/measles-complications-us-unchanged-posteradication. May 15, 2019.